BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ganji C, Farran B. Current clinical trials for epigenetic targets and therapeutic inhibitors for pancreatic cancer therapy. Drug Discov Today 2021:S1359-6446(21)00563-8. [PMID: 34952224 DOI: 10.1016/j.drudis.2021.12.013] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Hu W, Li M, Wang Y, Zhong C, Si X, Shi X, Wang Z. Comprehensive bioinformatics analysis reveals the significance of forkhead box family members in pancreatic adenocarcinoma. Aging (Albany NY) 2023;15:92-107. [PMID: 36622275 DOI: 10.18632/aging.204455] [Reference Citation Analysis]
2 Chen X, Yuan Q, Liu J, Xia S, Shi X, Su Y, Wang Z, Li S, Shang D. Comprehensive characterization of extracellular matrix-related genes in PAAD identified a novel prognostic panel related to clinical outcomes and immune microenvironment: A silico analysis with in vivo and vitro validation. Front Immunol 2022;13:985911. [DOI: 10.3389/fimmu.2022.985911] [Reference Citation Analysis]
3 Koltai T, Reshkin SJ, Carvalho TMA, Di Molfetta D, Greco MR, Alfarouk KO, Cardone RA. Resistance to Gemcitabine in Pancreatic Ductal Adenocarcinoma: A Physiopathologic and Pharmacologic Review. Cancers (Basel) 2022;14:2486. [PMID: 35626089 DOI: 10.3390/cancers14102486] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]